Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Leukemia, Myeloid, Acute 12Sarcoma, Kaposi 5HIV Infections 5Acquired Immunodeficiency Syndrome 5Myeloproliferative Disorders 4Neoplasm Metastasis 2Myelodysplastic Syndromes 2Leukemia, Monocytic, Acute 2Triple Negative Breast Neoplasms 1Thrombocythemia, Essential 1Rectal Neoplasms 1Primary Myelofibrosis 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Biphenotypic, Acute 1Hematologic Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Burkitt Lymphoma 1Breast Neoplasms 1Breast Cancer Metastatic 1Advanced Cancer 1

Interventions

Cyclophosphamide 62fludarabine phosphate 55Peripheral Blood Stem Cell Transplantation 44ruxolitinib 41Tacrolimus 41Busulfan 40Mycophenolic Acid 36Whole-Body Irradiation 32Antilymphocyte Serum 29Methotrexate 27Cyclosporine 27fludarabine 24Melphalan 19Filgrastim 19Radiotherapy 15Methylprednisolone 13thymoglobulin 12Stem Cell Transplantation 12Etoposide 12Cord Blood Stem Cell Transplantation 12Azacitidine 12Sirolimus 11Flow Cytometry 1011-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 10Psychiatric Rehabilitation 9Decitabine 9Specimen Handling 8Prednisone 8Cytarabine 8navitoclax 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Primary Myelofibrosis × Liposomes × Clear all
NCT03878199 2026-04-24

Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms

Ohio State University Comprehensive Cancer Center

Phase 1/2 Terminated
12 enrolled 15 charts
Myeloid

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡